COMMUNIQUÉS West-GlobeNewswire

Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
16/02/2024
EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug development for the [...]
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
16/02/2024
Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio EMERYVILLE, Calif., Feb. 16, 2024 (GLOBE [...]
Annual General Meeting in ALK-Abelló A/S on 14 March 2024
16/02/2024
ALK ( ALKB:DC / OMX: ALK B / AKBLF ): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 14 March 2024 at 4:00 PM (CET) at ALK-Abelló A/S, 1 Bøge Allé, 2970 Hørsholm, Denmark. The agenda of the [...]
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024
16/02/2024
NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter and full year ended December 31 [...]
L’hôpital spécialisé et centre de recherche King Faisal confirme sa position de leader mondial et régional de la santé
16/02/2024
RIYAD, Arabie Saoudite, 16 févr. 2024 (GLOBE NEWSWIRE) -- Pour la deuxième année consécutive, l’hôpital spécialisé et centre de recherche King Faisal, ci-après « KFSH&RC » pour King Faisal Specialist Hospital & [...]
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16/02/2024
WATERTOWN, Mass., Feb. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with retinal [...]
Pharvaris Announces Extraordinary Meeting of Shareholders
16/02/2024
ZUG, Switzerland , Feb. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks [...]
Vistin Pharma ASA: Key information relating to the proposed cash dividend
16/02/2024
The Board of Directors of Vistin Pharma ASA plans to propose to distribute a cash dividend of total NOK 1.00 per share, to be paid partly in June and November, for the accounting year of 2023. The formal decision [...]
Smart Immune appoints key new members to its Board of Directors
16/02/2024
Smart Immune appoints key new members to its Board of Directors PARIS, France, 16 February 2024 – Smart Immune, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T cell progenitor therapy [...]
Vistin Pharma ASA: Fourth quarter and preliminary 2023 financial results
16/02/2024
Oslo, Norway, 16 th of February 2024 Vistin Pharma ASA (Vistin Pharma, OSE: VISTN) today announces the financial results for the fourth quarter of 2023. Vistin delivers another strong quarter with a 12% revenue growth [...]
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
16/02/2024
Japan first in the world to approve Dupixent ® for chronic spontaneous urticaria (CSU) Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the [...]
Communiqué de presse : Le Japon est le premier pays dans le monde à approuver Dupixent® pour le traitement de l’urticaire chronique spontanée
16/02/2024
Le Japon est le premier pays dans le monde à approuver Dupixent ® pour le traitement de l’urticaire chronique spontanée L’approbation est fondée essentiellement sur les résultats d’un essai de phase III ayant montré que [...]
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
16/02/2024
Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved indication for Dupixent in Japan and the sixth indication for Dupixent globally [...]
Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office
16/02/2024
Tokyo, Japan and Cambridge, UK, 16 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), today announces that at a meeting held on 15 February 2024, its Board of Directors resolved to [...]
Sirona Biochem Provides Update on Loan
15/02/2024
VANCOUVER, British Columbia, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“ Sirona ” or the “ Company ”) announce that, further to its news release on January 29, 2024, [...]
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris
15/02/2024
EDMONTON, Alberta, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“ Ceapro ” or the “ Company ”) is pleased to announce that it has mailed and filed a management information circular dated [...]
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro
15/02/2024
Aeterna Zentaris Board recommends shareholders vote FOR all resolutions, to create a diversified biopharmaceutical company with a compelling value proposition More information and materials available at www.AEZSmerger. [...]
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3
15/02/2024
Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-term deposits at € 0.01 million 2 , and long-term deposit at €9.0 million 3 as of [...]
Inventiva publie ses informations financières préliminaires pour l’exercice fiscal 2023¹ et fait le point sur son étude clinique NATiV3
15/02/2024
Chiffre d’affaires de 17,5 millions d’euros pour l’année 2023, contre 12,2 millions d’euros sur la même période en 2022 Trésorerie et équivalents de trésorerie à 26,9 millions d’euros, dépôt à court-terme de 0,01 [...]

Pages